Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

被引:68
作者
Agulnik, Mark [1 ]
Oza, Amit M. [1 ]
Pond, Gregory R. [1 ]
Siu, Lillian L. [1 ]
机构
[1] Princess Margaret Hosp, Univ Hlth Network, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
关键词
D O I
10.1200/JCO.2005.03.4496
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To assess the impact and perceptions of patients, physicians, and institutional review board members ( IRBs) on the issue of mandatory serial tumor biopsies to acquire tissues for correlative studies. Patients and Methods Complementary, self-administered questionnaires were circulated to trial patients who had previously undergone serial research-related biopsies (TPs), clinic patients who had prior diagnostic but not research-related biopsies (CPs), academic medical oncologists in Canada (MOs), and IRBs at the affiliated academic centers. Results Ten (72%) of 14 TPs, 265 (82%) of 325 CPs, 137 (66%) of 209 MOs, and 142 (49%) of 291 IRBs responded. A 5% to 10% risk of a major biopsy complication was acceptable to 22% of CPs but only to 1% of MOs or IRBs. Anxiety was reported by 30% of TPs and 45% of CPs before their biopsies. More than 82% of MOs or IRBs believed the average patient would have at least borderline anxiety before their biopsy. Among the patients, 84% would authorize their samples for additional unrelated research and 75% would agree to genetic testing. Nearly all MOs and 86% of IRBs considered it ethical to request for additional unrelated research testing. With respect to genetic testing, 82% of MOs and 72% of IRBs would request it. Conclusion Although nearly all MOs and IRBs see the value in the biopsy, their threshold for acceptable risk is lower and they anticipate more associated anxiety than patients. Most patients recalled a tendency to tolerate their biopsies well with an average associated anxiety, and would allow their specimens to be tested for research purposes.
引用
收藏
页码:4801 / 4807
页数:7
相关论文
共 24 条
[1]   Tissue collection for correlative studies in childhood cancer clinical trials: Ethical considerations and special imperatives [J].
Anderson, BD ;
Adamson, PC ;
Weiner, SL ;
McCabe, MS ;
Smith, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4846-4850
[2]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[3]   Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].
Baselga, J ;
Albanell, J ;
Ruiz, A ;
Lluch, A ;
Gascón, P ;
Guillém, V ;
González, S ;
Sauleda, S ;
Marimón, I ;
Tabernero, JM ;
Koehler, MT ;
Rojo, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333
[4]   The validity of the Hospital Anxiety and Depression Scale - An updated literature review [J].
Bjelland, I ;
Dahl, AA ;
Haug, TT ;
Neckelmann, D .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 2002, 52 (02) :69-77
[5]   American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility [J].
Bruinooge, SS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2397-2406
[6]  
Daneshmand M, 2003, CLIN CANCER RES, V9, P2457
[7]   PERCEPTIONS OF CANCER-PATIENTS AND THEIR PHYSICIANS INVOLVED IN PHASE-I TRIALS [J].
DAUGHERTY, C ;
RATAIN, MJ ;
GROCHOWSKI, E ;
STOCKING, C ;
KODISH, E ;
MICK, R ;
SIEGLER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1062-1072
[8]  
Dowlati A, 2001, CLIN CANCER RES, V7, P2971
[9]   Phase I clinical trial design in cancer drug development [J].
Eisenhauer, EA ;
O'Dwyer, PJ ;
Christian, M ;
Humphrey, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :684-692
[10]   Clinical trial design for target-based therapy [J].
Fox, E ;
Curt, GA ;
Balis, FM .
ONCOLOGIST, 2002, 7 (05) :401-409